IGF-1 DES Chemistry: des(1-3) Sequence and Synthesis
A bench-level reference sheet on the des(1-3) truncation that defines IGF-1 DES, how the recombinant variant is expressed and folded, and what to read off the sequence before keeping one as a reference standard.
Sequence and Structure
IGF-1 DES is a truncated variant of insulin-like growth factor 1. The name is shorthand for des(1-3) IGF-1, which means the first three residues at the N-terminus of the parent peptide have been removed. Native IGF-1 is a 70-residue single-chain peptide, so deleting those three positions leaves a 67-residue molecule that is otherwise identical to the parent across the rest of its sequence.
Like full-length IGF-1, the molecule folds into a compact tertiary structure stabilized by three intramolecular disulfide bridges. Those bridges are central to its chemistry: the correctly folded, oxidized form is the species a reference standard is meant to represent, and the disulfide pattern is the single most important structural feature to preserve through production and handling. The des(1-3) truncation removes the short N-terminal segment that, in the parent peptide, participates in binding to IGF carrier proteins, which is why the variant is treated as a distinct chemical entity rather than a simple fragment.
Where It Sits in the IGF Family
The insulin-like growth factor family groups together single-chain peptides whose folds resemble proinsulin, including IGF-1, IGF-2, and engineered analogs derived from them. IGF-1 DES belongs to this family as an IGF-1 variant, sharing the same disulfide-stabilized core as the parent and differing only by the missing N-terminal tripeptide. Reading it as a member of that family is useful because the synthetic and analytical methods that apply to one IGF construct generally apply to the others.
Within the catalog, the closest relative is the elongated analog IGF-1 LR3, which modifies the same parent in the opposite direction by adding an N-terminal extension and a single substitution. The longer single-chain growth factor IGF-2 sits nearby as well. Treating these as a family rather than as unrelated molecules makes it easier to anticipate how a new entry will behave on the column and in storage.
Recombinant Expression
At 67 residues with three disulfide bridges, IGF-1 DES is well beyond the comfortable range for routine linear solid-phase synthesis, and the requirement for correct disulfide pairing makes a folded, expressed product the practical route. Research-grade material is most often produced by recombinant expression: the coding sequence for the truncated variant is expressed in a host system, the chain is recovered, and it is then refolded under controlled redox conditions so the three disulfide bonds form in their native arrangement.
Folding is the step that most shapes the final product. An incorrectly oxidized chain can form mispaired disulfides that have the same mass as the target but a different structure, so the refolding and purification stages are tuned to favor the single correct isomer. Purification then removes host-derived impurities and any misfolded species before the material is characterized. This expression-and-refold workflow is what distinguishes a disulfide-bridged growth factor like IGF-1 DES from the shorter linear peptides assembled by Fmoc solid-phase synthesis.
Characterization
Identity and purity for IGF-1 DES are established with the same two complementary tools used across the reference catalog. Reversed-phase HPLC reports the purity figure, the percentage of the total peak area attributable to the target, and it separates the main product from closely related truncation and misfolded species. Mass spectrometry confirms identity by matching the measured mass to the expected mass for the des(1-3) sequence, including the mass shift that the removed N-terminal residues introduce relative to full-length IGF-1.
Reading these together matters, and for a disulfide-bridged molecule it matters more than for a simple linear peptide. An HPLC purity number describes how much of the sample is the intended species relative to other UV-absorbing material, while the mass result confirms the molecule is the right sequence. Because correctly and incorrectly folded chains can share a mass, the chromatographic behavior carries extra weight in distinguishing the properly folded form. Both pieces of information describe the chemistry of the sequence, and a research chemist should expect to interpret them together rather than in isolation.
Stability and Storage
As lyophilized powder, IGF-1 DES is comparatively stable when kept cold, dry, and out of light. Long-term storage of the dry solid is typically at freezer temperatures, with the container protected from moisture so the hygroscopic powder does not pick up water on opening. Allowing a sealed vial to reach room temperature before it is opened helps avoid condensation on the cold contents.
Once reconstituted, the working solution is far less forgiving. Peptides in solution are subject to hydrolysis, oxidation, and adsorption to surfaces, and for a disulfide-bridged growth factor the oxidation pathway is a particular concern because disulfide scrambling can alter the fold without changing the mass. Reconstituted material is generally held cold, used within a short window, and protected from repeated freeze-thaw cycles. These are general handling principles for research peptides rather than claims about any one preparation, and the documentation for a given standard should be the reference of record for its own conditions.
What IGF-1 DES Is Studied For (Chemistry Only)
In a research-chemistry context, IGF-1 DES is of interest as a tractable model for studying how a defined N-terminal truncation changes the behavior of a disulfide-bridged growth factor. Comparing the des(1-3) variant with full-length IGF-1 and with the elongated IGF-1 LR3 analog lets chemists examine how sequence edits at the terminus affect folding, solubility, and chromatographic profile, and the variant serves as a well characterized reference point when validating expression and analytical methods on related IGF constructs.
That framing is deliberately limited to the bench. These materials are reference standards for laboratory research only, and nothing here describes or implies any human or veterinary use or outcome. The value of IGF-1 DES to a research chemist is as a chemistry subject, a defined variant whose behavior under expression, analysis, and storage is well understood and worth knowing in detail.
This overview is provided for laboratory and research use only. It is educational chemistry reference material and is not for human or veterinary consumption. Buyers are responsible for compliance with all applicable laws and regulations.
IGF-1 DES, answered for the bench
DES refers to des(1-3), meaning the first three N-terminal residues of IGF-1 have been removed. The result is a 67-residue truncated variant of the 70-residue parent peptide, so IGF-1 DES is shorthand for des(1-3) IGF-1.
IGF-1 DES is most often produced by recombinant expression, where the truncated coding sequence is expressed in a host system, then refolded so its three disulfide bridges form correctly and purified. The molecule is too long and disulfide-dependent for routine linear solid-phase synthesis.
Identity and purity are confirmed by reversed-phase HPLC, which reports purity as the percentage of total peak area attributable to the target, and by mass spectrometry, which matches the measured mass to the expected mass for the des(1-3) sequence. The two methods are read together.
As a lyophilized powder, IGF-1 DES is kept cold, dry, and out of light, with long-term storage at freezer temperatures. Once reconstituted it is far less stable and is generally held cold, used within a short window, and protected from repeated freeze-thaw cycles.